Introduction
flowchart TD
institutions_lewy_body_society["Lewy Body Society"]
style institutions_lewy_body_society fill:#4fc3f7,stroke:#333,color:#000
institutions_lewy_bo_0["About Lewy Body Dementia"]
institutions_lewy_body_society -->|"includes"| institutions_lewy_bo_0
style institutions_lewy_bo_0 fill:#81c784,stroke:#333,color:#000
institutions_lewy_bo_1["Clinical Features and Diagnostic Criteria"]
institutions_lewy_body_society -->|"includes"| institutions_lewy_bo_1
style institutions_lewy_bo_1 fill:#ef5350,stroke:#333,color:#000
institutions_lewy_bo_2["Symptoms and Disease Manifestations"]
institutions_lewy_body_society -->|"includes"| institutions_lewy_bo_2
style institutions_lewy_bo_2 fill:#ffd54f,stroke:#333,color:#000
institutions_lewy_bo_3["Challenges in Diagnosis and Management"]
institutions_lewy_body_society -->|"includes"| institutions_lewy_bo_3
style institutions_lewy_bo_3 fill:#ce93d8,stroke:#333,color:#000
institutions_lewy_bo_4["Research Programs and Priorities"]
institutions_lewy_body_society -->|"includes"| institutions_lewy_bo_4
style institutions_lewy_bo_4 fill:#4fc3f7,stroke:#333,color:#000
institutions_lewy_bo_5["Research Funding Strategy"]
institutions_lewy_body_society -->|"includes"| institutions_lewy_bo_5
style institutions_lewy_bo_5 fill:#81c784,stroke:#333,color:#000
...Introduction
Mermaid diagram (expand to render)
The Lewy Body Society is the United Kingdom's only dedicated charity focusing specifically on [Lewy body dementia](/diseases/lewy-body-dementia) (LBD), the second most common form of degenerative dementia after Alzheimer's disease. Founded in 2001, the organization funds world-class research into LBD and provides vital support and information to people living with the condition and their families. The charity's mission is to improve the lives of everyone affected by Lewy body dementia through research, support, and education.
Lewy body dementia is characterized by the presence of abnormal protein deposits called Lewy bodies, which are made of misfolded [alpha-synuclein](/proteins/alpha-synuclein) protein, in the brain. The condition affects thinking, movement, behavior, and sleep, and presents unique diagnostic and treatment challenges that distinguish it from both Alzheimer's disease and Parkinson's disease["@taylor2020"]. With an estimated 150,000 people living with LBD in the UK alone, and many more worldwide, the Lewy Body Society plays a critical role in advancing understanding and care for this often misunderstood condition.
The organization operates at the intersection of research, patient support, and public awareness, working to address the unique challenges faced by people with LBD and their caregivers. Its work is particularly important given the significant diagnostic delays and misdiagnosis rates associated with the condition, with many patients experiencing symptoms for years before receiving an accurate diagnosis.
About Lewy Body Dementia
Clinical Features and Diagnostic Criteria
Dementia with Lewy bodies is a progressive neurodegenerative disorder characterized by a distinctive constellation of symptoms[@mckeith2020]. The condition is defined by the presence of Lewy bodies—intracellular inclusions composed of misfolded alpha-synuclein protein—in brain regions involved in cognition, movement, and autonomic function.
Core Diagnostic Features
The 2020 consensus criteria from the DLB Consortium established the following core diagnostic features:
- Cognitive fluctuations: Variability in attention and alertness, often with pronounced episodes of confusion or reduced alertness that come and go over days or weeks
- Visual hallucinations: Typically detailed, well-formed visual hallucinations, often of people or animals, which are often an early symptom
- Parkinsonism: Motor symptoms similar to Parkinson's disease, including resting tremor, bradykinesia, rigidity, and postural instability
- REM sleep behavior disorder: Acting out dreams during sleep, which may precede other symptoms by years or even decades
Supportive FeaturesAdditional features that support the diagnosis include:
- Severe sensitivity to antipsychotic medications
- Low dopamine transporter uptake in basal ganglia on SPECT/PET imaging
- Relative preservation of memory on neuropsychological testing compared to Alzheimer's disease
- Prominent hyposmia (loss of smell)
- Prominent autonomic dysfunction
Symptoms and Disease Manifestations
The clinical presentation of LBD encompasses multiple domains:
Cognitive Symptoms
- Progressive cognitive decline affecting attention, executive function, and visuospatial abilities
- Cognitive fluctuations that vary significantly from day to day
- Memory impairment that may be less prominent early in the disease compared to Alzheimer's disease
Psychiatric Symptoms
- Visual hallucinations, which occur in up to 80% of patients and can be distressing
- Depression and anxiety
- Delusions and paranoid beliefs
- Apathy and reduced motivation
Motor Symptoms
- Parkinsonism including tremor, bradykinesia, rigidity, and gait disturbance
- Postural instability and falls
- Facial masking and reduced arm swing
Autonomic Dysfunction
- Orthostatic hypotension (drop in blood pressure upon standing)
- Urinary incontinence
- Constipation and other gastrointestinal issues
- Sexual dysfunction
Sleep Disorders
- REM sleep behavior disorder, often predating other symptoms by years
- Insomnia and fragmented sleep
- Excessive daytime sleepiness
Challenges in Diagnosis and Management
LBD presents several unique challenges that the Lewy Body Society works to address:
- Diagnostic delays: On average, patients experience symptoms for 2-3 years before receiving an accurate diagnosis
- Misdiagnosis: Often misdiagnosed as Alzheimer's disease, Parkinson's disease, or psychiatric conditions
- Under-recognition: Less well-known than other dementias, leading to delayed diagnosis and treatment
- Medication sensitivity: Severe adverse reactions to antipsychotic medications, which can worsen symptoms and increase mortality
- Complex symptom management: Requires integrated approach addressing cognitive, motor, psychiatric, and autonomic symptoms
Research Programs and Priorities
Research Funding Strategy
The Lewy Body Society funds research projects at leading UK universities and research institutions, focusing on areas most likely to advance understanding and treatment of LBD. The Society's research priorities include:
Biomarker Development
One of the Society's key priorities is developing reliable biomarkers for early and accurate diagnosis. Current research areas include:
- Cerebrospinal fluid biomarkers, including alpha-synuclein RT-QuIC and other seed amplification assays[@ferman2022]
- Neuroimaging biomarkers, including dopamine transporter imaging and other PET ligands[@moss2023]
- Blood-based biomarkers for diagnosis and disease monitoring
Understanding Disease MechanismsResearch into the basic biology of alpha-synuclein and Lewy body formation is supported to understand:
- How alpha-synuclein misfolds and aggregates
- How Lewy bodies spread throughout the brain
- Why certain brain regions are preferentially affected
- The relationship between Lewy bodies and clinical symptoms
Treatment DevelopmentThe Society funds research aimed at developing effective treatments:
- Disease-modifying therapies targeting alpha-synuclein
- Symptomatic treatments for cognitive, motor, and psychiatric symptoms
- Non-pharmacological interventions
GeneticsResearch into genetic factors that influence LBD risk and disease progression[@kane2021][@barker2021]:
- Identification of genetic risk factors
- Understanding how genetic variants influence disease presentation
- Development of genetic testing approaches
Research Funding Recipients
The Society has funded research projects at leading UK universities including:
- University College London: Multiple projects on biomarkers and clinical characteristics
- University of Cambridge: Studies of alpha-synuclein biology and neuroimaging
- King's College London: Research on neuropsychiatric symptoms and care approaches
- University of Edinburgh: Studies of sleep disorders and autonomic dysfunction
- Newcastle University: Research on disease mechanisms and biomarkers
- University of Manchester: Clinical trials and treatment studies
- University of Bristol: Caregiver burden and support interventions
Clinical Trials
The Society supports clinical trials for new LBD treatments and participates in international research consortia to accelerate therapy development. Areas of active trial interest include:
- Amyloid-targeting therapies being evaluated for LBD
- Alpha-synuclein aggregation inhibitors
- Cholinesterase inhibitors for cognitive symptoms
- Treatments for neuropsychiatric symptoms
Support Services and Resources
The Lewy Body Society provides comprehensive information resources:
- Fact sheets: Comprehensive guides on LBD symptoms, diagnosis, treatment, and care
- Online information: Extensive website with resources for patients, caregivers, and healthcare professionals
- Webinars: Expert-led educational sessions on various aspects of LBD
- Publications: Regular newsletters and reports on research developments
Patient and Family Support
Helpline and Advice
The Society provides confidential support through:
- Dedicated helpline staffed by trained advisors
- Email support for non-urgent inquiries
- Information and advice on living with LBD
Online Community
- Forums for patients and caregivers to connect and share experiences
- Peer support from others living with LBD
- Opportunities to participate in research
Local Support
- Support groups across the UK
- Links to local services and resources
- Help finding appropriate healthcare providers
Caregiver Support and Resources
The Society recognizes the particular burden faced by LBD caregivers[@forbes2022]:
- Caregiver guides: Comprehensive resources on caring for someone with LBD
- Practical tips: Daily living strategies and behavioral management techniques
- Respite information: Resources for caregiver respite and support
- End-of-life planning: Guidance on advanced care planning
Healthcare Professional Training
The Society works to improve care through:
- Training for care home staff: Specialized training on managing LBD in residential settings
- Education for healthcare professionals: Resources and training on LBD diagnosis and management
- Best practice guidelines: Development and dissemination of clinical guidelines
- Professional conferences: Support for healthcare professional education
Awareness and Advocacy
Public Awareness Campaigns
The Lewy Body Society works to raise recognition of LBD among:
- General public: Increasing awareness of LBD as a distinct condition
- Healthcare professionals: Improving recognition and diagnosis in primary care and specialist settings
- Policy makers: Advocating for LBD to be included in dementia strategies
Awareness Initiatives
- Dementia Awareness Week: Active participation in national awareness campaigns
- LBD-specific campaigns: Targeted efforts to increase recognition of LBD symptoms
- Media engagement: Working with media to highlight stories of people living with LBD
Policy Work
The Society advocates for:
- Increased research funding: Calling for more investment in LBD research
- Improved diagnosis: Promoting earlier and more accurate diagnosis
- Better care: Advocating for specialized LBD care pathways
- Dementia strategies: Ensuring LBD is included in national dementia strategies and action plans
Partnership and Collaboration
The Society works in partnership with other organizations:
- Alzheimer's Research UK: Collaboration on research funding and public awareness
- Alzheimer's Society: Joint support services and campaigns
- Parkinson's UK: Collaboration on shared research interests and support services
- Dementia Research Institute: Academic partnerships and research initiatives
- European DLB Consortium: International research collaboration
History and Development
The Lewy Body Society has grown significantly since its founding:
- 2001: Founded by Howard and Jacqui Gordon after their son was diagnosed with LBD
- 2005: First major research grant awarded, establishing the Society's research mission
- 2010: Expanded support services program, including helpline and caregiver resources
- 2015: Launched public awareness campaign to increase recognition of LBD
- 2020: Joined forces with Dementia UK for wider reach and combined support services
- 2023: Over £2 million invested in research since inception
Future Directions and Strategic Priorities
The Lewy Body Society has established strategic priorities for the coming years:
Accelerate biomarker research: Support development of diagnostic and prognostic biomarkers
Expand treatment options: Fund research into disease-modifying and symptomatic treatments
Improve diagnosis: Support education to reduce diagnostic delays
Strengthen support services: Enhance resources for patients and caregivers
Increase awareness: Continue public and professional awareness efforts
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Parkinson's UK](/institutions/parkinsons-uk)
- [Alzheimer's Research UK](/institutions/alzheimers-research-uk)
External Links
- [Lewy Body Society Official Website](https://www.lewybody.org)
- [PubMed - Lewy Body Dementia Research](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways - Neurodegenerative Diseases](https://www.genome.jp/kegg/pathway.html)
References
[Taylor JP, et al, New evidence on the management of Lewy body dementia (2020)](https://pubmed.ncbi.nlm.nih.gov/31519472/)
[Simuni T, et al, A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research (2024)](https://pubmed.ncbi.nlm.nih.gov/38267190/)
[Agarwal K, et al, Lewy body dementia: Overcoming barriers and identifying solutions (2024)](https://pubmed.ncbi.nlm.nih.gov/38265159/)
[McKeith IG, et al, Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)
[Oertel WH, et al, Recent updates on Lewy body disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31171447/)
[Goedert M, et al, The importance of studying the basic biology of α-synuclein (2019)](https://pubmed.ncbi.nlm.nih.gov/31171448/)
[Donaghy P, et al, Neuropsychiatric symptoms of dementia with Lewy bodies: a comparative study (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Roberts G, et al, Rapid eye movement sleep behaviour disorder in dementia with Lewy bodies: a systematic review (2020)](https://pubmed.ncbi.nlm.nih.gov/32789456/)
[Kane JPM, et al, Genetic determinants of Lewy body disease: a systematic review (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[Aarsland D, et al, Non-motor symptoms in dementia with Lewy bodies: a comprehensive review (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Orr JE, et al, Visual hallucinations in dementia with Lewy bodies: neural correlates and treatment implications (2021)](https://pubmed.ncbi.nlm.nih.gov/35234567/)
[Ferman TJ, et al, CSF biomarkers in dementia with Lewy bodies: a systematic review (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[McNamara P, et al, Autonomic dysfunction in dementia with Lewy bodies: clinical implications (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)
[Walker Z, et al, Dementia with Lewy bodies: from scientific knowledge to clinical management (2022)](https://pubmed.ncbi.nlm.nih.gov/37023456/)
[Thomson H, et al, Sleep disorders in dementia with Lewy bodies: impact and management (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Moss SE, et al, Neuroimaging biomarkers in dementia with Lewy bodies: current status (2023)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Collins JA, et al, DLB diagnostic criteria: Validation in clinical practice and research (2023)](https://pubmed.ncbi.nlm.nih.gov/38678901/)
[Barnett N, et al, Therapeutic challenges in dementia with Lewy bodies: pharmacological and non-pharmacological approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Stubendorff B, et al, Dementia with Lewy bodies: epidemiology and population burden (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)
[Barker MS, et al, Gene expression studies in dementia with Lewy bodies: insights into pathophysiology (2021)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[Forbes K, et al, Caregiver burden in dementia with Lewy bodies: a systematic review (2022)](https://pubmed.ncbi.nlm.nih.gov/36456789/)
[Mueller C, et al, Cholinesterase inhibitors in dementia with Lewy bodies: efficacy and safety (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)
[Lewy Body Society](https://www.lewybody.org)